Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Will depend alot on what % of each market we can actually reach if ava6000 is successful and there is no like for like competition or no other cure for cancer then there is no reason it wouldn't be used in all applicable cases, soo the percentages could be higher depending how successful it is.
Also there is the implication of saving and prolonging many lives.
In ten years global antibody market to be worth 371 billion annually.
In ten years the global oncology market will be worth 156 billion annually.
If the Affimer platform continues to out perform traditional antibodies and aptamers and is proven in our covid-19 products aswell as Ava6000 then a global market share of 15-20% is easily achievable in ten years time 55.65-74.2 billion annually in Affimer licensing for Avacta.
If Ava6000 is successful Avacta plan to take a market share of 5-10% of the global market tho this could be alot more in ten years time.
I believe if it is half as successful in humans as in animals you could be looking at more than 20% of goblal market in ten years time 31.2 billion annually for Avacta.
Ava6000 has a much better chance of being successful in the clinic as it is not a new drug it is a transporting and release vehicle for Doxorubicin which is a very effective .there will also only be 2 stages as apposed to 3.
The revenue from our covid products is going to fund our clinical trials and enable the other Ava products into the clinic without any dilution or further fund raising,also funding further R&D.
When you look at the numbers it's easy to see why growing companies are bought out.
Avacta have so many chances at success when you look beyond then next few years the sky is the limit.
Personally I hope we can fend off any take over bid as Avacta are the next giant in the making.
Can't imagine big Al agreeing to do an interview solely to discuss royalties.
News on BAMS is due so could be a possibility for Monday pre interview.
Could be a number of other pieces of news RNS'd
Pre interview which could give them plenty to discuss.
Another exciting week to look forward to.
Mumbo,
Because its now in CV ,once CV has started it will completed in the set time scale regardless of how good it may or may not be it is a process.
There are no scientific , manufacturing or other complications that can hold it up it is now a process and will be completed before the end of the month, and might actually be sooner than we think.
There is absolutely no doubt that we will be in a position to tender if the CV data meets criteria. Which I am fairly confident it will.
Medusa19's own test is basically pointless now they can't be making many sales.
They have invested 10s of millions of their own capital so you can be sure they will be manufacturing something that is going to sell,
The tie up with Avacta already in place leads me to the conclusion it must be our tests they are manufacturing.
We need capacity they need something to manufacture it makes sense.
The deal will probably be pending CV figures hence no RNS.
Big Al did mention in latest video about talks with other UK manufactures.
Definitely alot of coincidences.
There really needs to be an official announcement about the differences between LFT's and PCR.
Listening to Martin Lewis on andrew mar show saying LFT's are not as accurate as PCR and creating alot of false negatives.
LFT's are designed to catch people who are infectious!!!! Not to tell you if you have the virus!!!!
They should never be compared.
The public need to know this or there is always going to be bad press around them.
This has got the be explained in one of the daily briefings.
The test the world needs must be accurate and easy to self test ie front of nose or saliva, nasopharyngeal tests if self administered are likely to be done incorrectly as they are soo uncomfortable.and also must be cheap for the masses.
As has been said there are loads of antigen tests around the world but there aren't many that have really high s/s with front of nose (1 or 2cm in) or saliva.
If our C/V data is the same as the clinical evaluation data then every country in the world would buy our tests if offered them.
The problem is manufacturing capicity, the government will take everything we can make as is seen with the 8 billion tender .
If we could make 40 million per month the government would still take them all.
If we want to get in to Europe and beyond we really need the giant factories in Asia to pop out close to 100 million per month which leads to the questuon of if this is the plan why are we only in talks with possible partners in SE Asia? Why are we not in the process of t/t with them as we know this will take circa 4 months, or is big Al waiting for CV before putting such deals in place?
It would be a shame if in the end if we produced the 10 million per month when there is a global market in the many many billions per year for the next 2 years .
Tho there is still many pieces of the puzzle missing as far as manufacturing capacity and the "consortium" are concerned ,I am sure everything will be revealed within the next 5 weeks and there will be a few surprises .
It's been an absolute rollercoaster of a year with avacta,and the journey has only just begun.
Here's to saving lives
Prolonging lives
Ending this pandemic
And early retirement
All big companies start as small companies and Avacta are now extremely well positioned to start the journey to giant status.
I too will be in this for the long run these opportunities don't come alone too often and must be grasped with both hands.
A few million per month from go.
Quickly scaling to 10 million per month.
On going conversations with oversea manufactures.
The way I see it is the mentioned capacity is for our product ,and we will be supplying Affimer reagents for the sovereign government test (consortium) which will be using the extra manufacturing capacity at BBI and Abingdon which will make up the numbers to 60 million per month .
She works for private care company , going to be using these twice per week.
Flowflex.
Https://www.provida-uk.com/flowflex-sars-cov2-rapid-antigen-test-kits.html